Amalgamated Bank’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Amalgamated Bank’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-794	Closed	-$15K	–	1412
2016 Q1	$15K	Buy	794 +69	+10%	+$1.33K	﹤0.01%	1284
2015 Q4	$19K	Sell	725 -60	-8%	-$2.08K	﹤0.01%	1195
2015 Q3	$36K	Buy	785 +6	+0.8%	+$226	﹤0.01%	1275
2015 Q2	$25K	Buy	779 +157	+25%	+$4.56K	﹤0.01%	1358
2015 Q1	$20K	Buy	622 +29	+5%	+$981	﹤0.01%	932
2014 Q4	$22K	Buy	593 +1	+0.2%	+$28	﹤0.01%	852
2014 Q3	$16K	Buy	592 +3	+0.5%	+$79	﹤0.01%	840
2014 Q2	$17K	Buy	589 +51	+9%	+$1.65K	﹤0.01%	869
2014 Q1	$20K	Sell	538 -2	-0.4%	-$76	﹤0.01%	832
2013 Q4	$22K	Buy	+540	New	+$21.1K	﹤0.01%	836

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Amalgamated Bank's NAVB Position: Q2 2016 in Review

Amalgamated Bank sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 794 shares — an estimated $15K sold.

Amalgamated Bank first reported a position in NAVB in Q4 2013 and held it in 10 quarters. The position peaked at $36K in Q3 2015. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Amalgamated Bank reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Amalgamated Bank sold 794 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $15K.
Amalgamated Bank first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 10 quarters.
Amalgamated Bank's Navidea Biopharmaceuticals Inc. position peaked at $36K in Q3 2015.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Amalgamated Bank's 13F filing for Q2 2016, filed 16 Aug 2016.